Thursday, January 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

U.S. Invests $36.3M in Pan-Coronavirus Vaccine Development

by Global Biodefense Staff
September 28, 2021
U.S. Invests $36.3M in Pan-Coronavirus Vaccine Development

Credit: NIAID

The awards are intended to fuel vaccine research for a diverse family of coronaviruses, with a primary focus on potential pandemic-causing coronaviruses, such as SARS-CoV-2.

A critical need remains for prophylactic vaccines offering broad protective immunity against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV).

The U.S. federal government announced funding this week to multidisciplinary teams to conduct research focused on incorporating understanding of coronavirus virology and immunology, immunogen design, and innovative vaccine and adjuvant platforms and technologies to discover, design, and develop pan-coronavirus vaccine candidates that provide broad protective immunity to multiple coronavirus strains.

The following awards have been issued:

University of Wisconsin, Madison
Project Title: PanCorVac (Center for Pan-Coronavirus Vaccine Development)
Grant: 1 P01AI165077-01

Brigham and Women’s Hospital, Boston
roject Title: Discovering Durable Pan-Coronavirus Immunity
Grant: 1 P01AI165072-01

Duke University, Durham, North Carolina
Project Title: Design and Development of a Pan-Betacoronavirus Vaccine
Grant: 1 P01AI158571-01A1

The awards are will address coronavirus diversity and infectious potential in humans, include innovative immunogen design and vaccine platforms, and approaches to elicit potent and durable pan-coronavirus immunity, and evaluate vaccine candidates in preclinical models.

The awardees are expected to be flexible in the response to emerging knowledge about SARS-CoV-2 immune responses and infection and factor in new information as vaccines candidates are developed.

The new awards total approximately $36.3 million and are funded by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) Division of Microbiology and Infectious Diseases through the Emergency Awards Notice of Special Interest (NOSI) on Pan-Coronavirus Vaccine Development Program Projects. Additional awards are expected from this NOSI, according to NIAID.

READ ALSO:

  • The Search for a Single Vaccine Against Coronaviruses Yet to Come JAMA Network
  • A ‘Universal’ Coronavirus Vaccine to Prevent the Next Pandemic Scientific American
  • Decades-old SARS virus infection triggers potent response to COVID vaccines Nature
Tags: CoronavirusCOVID-19Drug DevelopmentEditor PickNIAIDSARS-CoV-2Vaccines

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy